Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Vytášek, Richard ^a   Šedová, Liliana ^b   Vilím, Vladimír ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INFLIXIMAB; LYSINE DERIVATIVE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 103 E3; MONOCLONAL ANTIBODY 8 C1; PREDNISOLONE; RHEUMATOID FACTOR; RIBOSE; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; ANTIGEN; CORTICOSTEROID; DIAGNOSTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; ENZYME IMMUNOASSAY; FEMALE; GENDER; GLYCATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; HOSPITALIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS; ARTHRITIS, RHEUMATOID; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOENZYME TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OSTEOARTHRITIS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 77953562098     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-83     Document Type: Article

References (45)

1. N-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. K Ikeda T Higashi H Sano Y Jinnouchi M Yoshida T Araki S Ueda S Horiuchi, Biochemistry 1996 35 8075 8083 10.1021/bi9530550 8672512
2. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. DR Sell VM Monnier, J Biol Chem 1989 264 21597 21602 2513322
3. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. Q Zhang JM Ames RD Smith JW Baynes TO Metz, J Peoteome Res 2009 8 754 769 10.1021/pr800858h
4. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. M Takahashi M Suzuki K Kushida S Miyamoto T Inoue, Brit J Rheumatol 1997 36 637 642 10.1093/rheumatology/36.6.637
5. Increased concentrations of serum pentosidine in rheumatoid arthritis. J Rodriguez-Garcia JR Requena S Rodriguez-Segade, Clin Chem 1998 44 250 255 9474020
6. Comparison of the concentration of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. JR Chen M Takahashi M Suzuki K Kushida S Miyamoto T Inoue, Rheumatology (Oxford) 1999 38 1275 1278 10.1093/rheumatology/38.12.1275 10587559
7. The advanced glycation end-product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. GE Hein M Köhler P Oelzner G Stein S Franke, Rheumatol Int 2005 26 137 141 10.1007/s00296-004-0518-1 15580352
8. Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. L enolt M Braun J Vencovsk L edov K Pavelka, Physiol Res 2007 56 771 777 17298211
9. Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis. Y Kageyama M Takahasi T Nagafusa E Torikai A Nagano, Mod Rheumatol 2007 17 398 402 10.1007/s10165-007- 0607-6 17929132 (Pubitemid 47593488)
10. Reduction of oxidative stress marker levels by anti-TNF antibody, infliximab, in patients with rheumatoid arthritis. Y Kageyama M Takahasi T Ichikawa E Torikai A Nagano, Clin Exp Rheumatol 2008 26 73 80 18328150 (Pubitemid 351385258)
11. Etarnecept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Y Kageyama M Takahasi T Nagafusa E Torikai A Nagano, Rheumatol Int 2008 28 245 251 10.1007/s00296-007-0419-1 17661050
12. Increased pentosidine, an advanced glycation end-product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. T Miyata N Ishiguro Y Yasuda T Ito M Nangaku H Iwata K Kurokawa, Biochem Biophys Res Commun 1998 244 45 49 10.1006/bbrc.1998.8203 9514872
13. A sensitive and specific ELISA for plasma pentosidine. Y Izuhara M Miyata Y Ueda D Suzuki K Asahi R Inagi H Sakai K Kurokawa, Nephrol Dial Transplant 1999 14 576 580 10.1093/ndt/14.3.576 10193802
14. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. T Sanaka T Funaki T Tanaka S Hoshi J Niwayama T Taitoh H Nishimura C Higuchi, Nephron 2002 91 64 73 10.1159/000057606 12021521
15. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. S Horiuchi N Araki Y Morino, J Biol Chem 1991 266 7329 7332 2019568
16. Conventional antibody against N-(carboxymethyl)lysine (CML) shows cross-reaction to N-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody. W Koito T Araki S Horiuchi R Nagai, J Biochem (Tokyo) 2004 136 831 837
17. Immunochemical detection of N-(carboxyetlyl)lysine using a specific antibody. R Nagai Y Fujiwara K Mera K Yamagata M Sakashita M Takeya, J Immunol Met 2008 332 112 120 10.1016/j.jim.2007.12.020
18. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. JV Valencia SC Weldon D Quinn GH Kiers J DeGroot JM TeKoppele TE Hughes, Anal Biochem 2004 324 68 78 10.1016/j.ab.2003.09.013 14654047
19. N-(carboxyetlyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. MU Ahmed E Brinkmann Frye TP Degenhardt SR Thorpe JW Baynes, Biochem J 1997 324 565 570 9182719
20. Optimization of electrofusion parameters for efficient production of murine hybridomas. DA Stenger RT Kubiniec WJ Purucker H Liang SW Hui, Hybridoma 1988 7 505 518 10.1089/hyb.1988.7.505 3198135
21. Polyvinylpyrrolidone as a blocking agent in immunochemical studies. JW Haycock, Anal Biochem 1993 208 397 399 10.1006/abio.1993.1068 8095775
22. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. ML Prevoo MA van T'Hof HH Kuper MA van Leeuwen LB van De Putte PL van Riel, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
23. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. C Bombardier DD Gladman MB Urowitz D Caron CH Chang, Arthritis Rheum 1992 35 630 640 10.1002/art.1780350606 1599520
24. Radiological assesment of osteoarthritis. JH Kellgren JS Lawrence, Ann Rheum Dis 1957 16 494 501 10.1136/ard.16.4.494 13498604
25. Non enzymatic glycated proteins in the blood and cardiovascular disease. G Misciagna G De Michele M Trevisan, Curr Pharm Des 2007 13 3688 3695 10.2174/138161207783018545 18220807
26. Nonenzymatic glucosylation of lysine residues in albumin. JW Baynes SR Thorpe MH Murtiashaw, Methods Enzymol 1984 106 88 98 6436646
27. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. Q Zhang N Tang AA Schepmoes LS Phillips RD Smith TO Metz, J Peoteome Res 2008 7 2025 2032 10.1021/pr700763r
28. Specific glycation of albumin depends on its half-life. ED Schleicher B Olgemöller E Wiedenmann KD Gerbitz, Clin Chem 1993 39 625 628 8472356
29. Effect of collagen turnover on the accumulation of advanced glycation end products. N Verzijl J DeGroot SR Thorpe RA Bank N Shaw TJ Lyons JWJ Bijlsma FPJG Lafeber JW Baynes JT TeKoppele, J Biol Chem 2000 275 39027 39031 10.1074/jbc.M006700200 10976109
30. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. LJ Sparvero D Asafu-Adjei R Kang D Tang N Amin J Im R Rutledge B Lin AA Amoscato HJ Zeh MT Lotze, J Transl Med 2009 7 10.1186/1479-5876-7-17 19292913
31. N-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. T Kislinger C Fu B Huber W Qu A Taguchi SD Yani N Hofmann SF Yan M Pischetsrieder D Stern AM Schmidt, J Biol Chem 1999 274 31740 31749 10.1074/jbc.274.44.31740 10531386
32. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. WJ van Venrooij GJM Prujin, Arthritis Res Ther 2000 2 249 251
33. A new model for an etiology of rheumatoid arthritis. Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. L Klareskog P Stolt K Lundberg H Källberg C Bengtsson J Grunewald J Rönnelid H Erlandsson Harris A-K Ulfgren S Rantapää- Dahlquist A Eklund L Padyukov L Alfredsson the Epidemiological Investigation of Rheumatoid Arthritis Study Group, Arthritis Rheum 2006 54 38 46 10.1002/art.21575 16385494
34. Posttranslational protein modifications: new flavors in the menu of autoantigens. HA Doyle MJ Mamula, Curr Opin Rheum 2002 14 244 249 10.1097/00002281-200205000-00009 (Pubitemid 34439088)
35. Posttranslational modifications of self-antigens. HA Doyle MJ Mamula, Ann N Y Acad Sci 2005 1050 1 9 10.1196/annals.1313.001 16014515
36. Molecular mechanisms of autoimmunity. MZ Atassi P Casali, Autoimmunity 2008 41 123 132 10.1080/08916930801929021 18324481
37. Consequence of neo-antigenicity of the "altered self". P Eggleton R Haigh PG Winyard, Rheumatology (Oxford) 2008 47 567 571 10.1093/rheumatology/ken014 18316337
38. Glyco-biomarkers: Potential determinants of cellular physiology and pathology. A Alavi JS Axford, Disease Markers 2008 25 193 205 19126964
39. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. RB Parekh RA Dwek BJ Sutton DL Fernandez A Leung D Stanworth TW Rademacher T Mizoguchi T Taniguchi K Matsuta F Takeuchi Y Nagano T Miyamoto A Kobata, Nature 1985 316 452 457 10.1038/316452a0 3927174
40. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. M Tomana RE Schrohenloher WJ Koopman G Alarcon WA Paul, Arthritis Rheum 1988 31 333 338 10.1002/art.1780310304 3358797
41. A longitudinal study of the relationship between galactosylation degree of IgG and rheumatoid factor titer and avidity during long-term immunization of rabbits with BSA. D iri N Miloevi-Jovi V Ili S Petrovi Autoimmunity 2005 38 409 416 10.1080/08916930500241785 16278145
42. Diagnosic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. H Das T Atsumi Y Fukushima H Shibuya K Ito Y Yamada Y Amasaki K Ichikava O Amengual T Koike, Clin Rheumatol 2004 23 218 222 10.1007/s10067-003- 0860-9 15168148
43. Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. MC Lu SC Hsieh NS Lai KJ Li CH Wu CL Yu, Clin Exp Rheumatol 2007 25 716 721 18078619
44. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. S Ligier PR Fortin MM Newkirk, Br J Rheumatol 1998 37 1307 1314 10.1093/rheumatology/37.12.1307 9973155
45. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. MD Lucey MM Newkirk C Neville K Lepage PR Fortin, J Rheumatol 2000 27 319 323 10685791